

SMSO Policy Manual

Radiopharmaceuticals

Executive Sponsor: Melissa Rusk, VP Operations

Issuing Department: Claims

Gate Keeper: Terry Snyder, Director Claims

COMPLIANCE STATEMENT:

Enforcement:	All members of the workforce are responsible for compliance with this policy. Failure to abide by the requirements of this policy may result in corrective action, up to and including termination. Workforce members are responsible for reporting any observed violations of this policy.
Review Schedule:	This policy will be reviewed and updated as necessary and no less than every two years.
Monitoring and Auditing:	The Issuing/Collaborating Department(s) is responsible for monitoring compliance with this policy.
Documentation:	Documentation related to this policy must be maintained for a minimum of 10 years.

Applies to:

- | | |
|--|---|
| ☒ SummaCare | ☒ Apex |
| ☒ Summa Management Service Organization (SMSO) | ☒ Summa Insurance Company |

Line of Business:

- | | |
|---|---|
| ☒ Commercial Groups | ☒ Medicare |
| ☐ Medicare Supplemental | ☒ On-Exchange |
| ☒ Off-Exchange | ☒ Self-Funded |

1.0 Purpose:

- 1.1 The purpose of this policy is to outline SummaCare's reimbursement for radiopharmaceuticals and contrast material

2.0 Policy:

- 2.1.1 All providers will be reimbursed based on this policy for the categories of procedures listed below based on industry trends and appropriate utilization and billing practice for the office setting and outpatient places of service.
 - 2.1.1.1 **Limitations and Exclusions:**
While reimbursement is considered, payment determination is subject to, but not limited to:
 - 2.1.1.2 Member Plan Benefits
 - 2.1.1.3 Provider Participation Agreement
 - 2.1.1.4 Routine claim editing logic, including but not limited to incidental or mutually exclusive logic, and medical necessity
 - 2.1.1.5 Prior Authorization Requirements

3.0 Procedure:

- 3.1 All radiopharmaceutical diagnostic imaging isotopes or agents used in the performance of diagnostic nuclear medicine procedures will be reimbursed except as listed below:
 - 3.1.1 Contrast agents billed with an MRI will be denied as included in reimbursement of the primary service.
 - 3.1.2 Radiopharmaceuticals billed with a PET scan will be denied as included in reimbursement of the primary service.
 - 3.1.3 Materials billed with a CT or other radiographic studies will be denied as included in reimbursement of the primary service.

4.0 References:

- 4.1 Internal Standard
- 4.2 None
- 4.3 None

4.4 None

5.0 Definitions:

None

6.0 Key Words or Aliases (Optional):

6.1 CT Scan, MRI, PET, Radiopharmaceuticals

ORIGINAL EFFECTIVE DATE: 1/1/21

REVIEWED: 9/26/22

REVISED: 9/26/22 (added update to A9500)